Rochester, MN - A new case series of patients with a previous stroke suggests that transcatheter device closure of patent foramen ovale (PFO) and atrial septal defect (ASD) is safe and eliminated ...

The US Food and Drug Administration (FDA) has approved the Gore Cardioform septal occluder for closure of patent foramen ovale (PFO) to prevent recurrent ischemic stroke, the manufacturer, WL Gore & ...

FLAGSTAFF, Ariz., March 11, 2021 /CNW/ -- W. L. Gore & Associates (Gore), today announced that Gore REDUCE Study long-term follow-up results were published in the March 2021 issue of The New England ...

FLAGSTAFF, Ariz., June 4, 2019 /PRNewswire/ -- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration's (FDA's) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder ...

ORLANDO, FL—Three months of clopidogrel on top of aspirin appears to reduce the number and severity of migraines following atrial septal defect (ASD) closure, a new study suggests. The findings, while ...

A pooled analysis of 3 studies comparing PFO closure with optimal medical therapy in patients with cryptogenic stroke offers evidence that closure generally produces better outcomes. That being said, ...

The much-anticipated results of the international RESPECT and PC trials, first presented at TCT 2012, have now been published in the NEJM. In the primary analysis of each study, closure of patent ...

Editor's Note: This article is made possible through a sponsored content partnership with New Hanover Regional Medical Center. Structural heart disease includes conditions in which the heart’s valves, ...

CAUTION: Investigational device. Limited by United States law to investigational use. The Gore RELIEF Clinical Study is evaluating the safety and efficacy of transcatheter closure of patent foramen ...

Encore Medical aims to raise $17.25M in IPO funding for FDA heart device trials. Click here to read the latest analysis on ...